{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T13:33:28Z","timestamp":1791812008942,"version":"4.3.4"},"reference-count":205,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Japan Society for the Promotion of Science (JSPS) KAKENHI","award":["22K05479"],"award-info":[{"award-number":["22K05479"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), are growing global health concerns. However, pharmacological therapies for MASLD\/MASH have not yet been established. Dietary interventions and their bioactive components have been explored as strategies to mitigate MASLD and MASH progression. Although specific nutrients and bioactive compounds have exhibited potential therapeutic benefits, they also exacerbate adverse outcomes. In this comprehensive review, we synthesize the protective and exacerbating or sometimes dual effects of key macronutrients, including fatty acids (saturated, unsaturated, and trans fats) and carbohydrates (fructose, glucose, and sucrose), and bioactive compounds and micronutrients, in the context of MASLD management. The evidence suggests that coffee-derived compounds, such as caffeine and chlorogenic acid, may attenuate liver injury. However, the effects on MASLD severity are inconsistent. Diets high in saturated fatty acids exacerbate MASLD pathogenesis, whereas moderate intake (7\u201310% of total energy) may confer metabolic benefits. Other bioactive compounds and micronutrients have been explored for their diverse roles in hepatic lipid metabolism and insulin sensitivity. Although current evidence supports the therapeutic potential of specific dietary nutrients and bioactive compounds in the management of MASLD, inconsistencies in results highlight the need for more robust, well-controlled studies, including clinical trials, to clarify the preventive and therapeutic standards for balanced food interventions in MASLD management. In particular, well-designed clinical trials are necessary before clinical application. Although this is a narrative review and the literature retrieval may be biased, we covered a wide variety of substances.<\/jats:p>","DOI":"10.3390\/nu17132211","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T06:01:33Z","timestamp":1751522493000},"page":"2211","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Food Nutrients and Bioactive Compounds for Managing Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comprehensive Review"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4216-6829","authenticated-orcid":false,"given":"Erdenetsogt","family":"Dungubat","sequence":"first","affiliation":[{"name":"Department of Molecular Pathology, Tokyo Medical University, Shinjuku-ku, Tokyo 160-8402, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Fujikura","sequence":"additional","affiliation":[{"name":"Department of Molecular Pathology, Tokyo Medical University, Shinjuku-ku, Tokyo 160-8402, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7052-4289","authenticated-orcid":false,"given":"Masahiko","family":"Kuroda","sequence":"additional","affiliation":[{"name":"Department of Molecular Pathology, Tokyo Medical University, Shinjuku-ku, Tokyo 160-8402, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Fukusato","sequence":"additional","affiliation":[{"name":"General Medical Education and Research Center, Teikyo University, Itabashi-ku, Tokyo 173-8605, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9610-2137","authenticated-orcid":false,"given":"Yoshihisa","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Molecular Pathology, Tokyo Medical University, Shinjuku-ku, Tokyo 160-8402, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver, European Association for the Study of Diabetes, and European Association for the Study of Obesity (2024). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary. Diabetologia, 67, 2375\u20132392.","DOI":"10.1007\/s00125-024-06196-3"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.3350\/cmh.2025.0045","article-title":"KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025","volume":"31","author":"Sohn","year":"2025","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jhep.2024.08.011","article-title":"Association of food insecurity with MASLD prevalence and liver-related mortality","volume":"82","author":"Younossi","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Ranneh, Y., Bedir, A.S., Abu-Elsaoud, A.M., and Al Raish, S. (2024). Polyphenol Intervention Ameliorates Non-Alcoholic Fatty Liver Disease: An Updated Comprehensive Systematic Review. Nutrients, 16.","DOI":"10.3390\/nu16234150"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"100375","DOI":"10.1016\/j.advnut.2025.100375","article-title":"Macronutrient Modulation in Metabolic Dysfunction-Associated Steatotic Liver Disease\u2014The Molecular Role of Fatty Acids compared with Sugars in Human Metabolism and Disease Progression","volume":"16","author":"Mullin","year":"2025","journal-title":"Adv. Nutr."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3350\/cmh.2024.0782","article-title":"Bioactive metabolites: A clue to the link between MASLD and CKD?","volume":"31","author":"Chen","year":"2025","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Kakazu, E., Mino, M., and Kanto, T. (2025). Role of amino acids in the regulation of hepatic gluconeogenesis and lipogenesis in metabolic dysfunction-associated steatotic liver disease. Clin. Mol. Hepatol.","DOI":"10.3350\/cmh.2025.0048"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S244","DOI":"10.3350\/cmh.2022.0364","article-title":"Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease","volume":"29","author":"Semmler","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41574-019-0256-9","article-title":"The regulation of hepatic fatty acid synthesis and partitioning: The effect of nutritional state","volume":"15","author":"Hodson","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"G1310","DOI":"10.1152\/ajpgi.00365.2011","article-title":"Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2","volume":"302","author":"Miura","year":"2012","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1172\/JCI28898","article-title":"TLR4 links innate immunity and fatty acid-induced insulin resistance","volume":"116","author":"Shi","year":"2006","journal-title":"J. Clin. Investig."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1055\/s-0028-1091980","article-title":"Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease","volume":"28","author":"Malhi","year":"2008","journal-title":"Semin. Liver Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.2337\/db13-1622","article-title":"Overfeeding polyunsaturated and saturated fat causes distinct effects on liver and visceral fat accumulation in humans","volume":"63","author":"Rosqvist","year":"2014","journal-title":"Diabetes"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.cell.2012.02.017","article-title":"Mechanisms for insulin resistance: Common threads and missing links","volume":"148","author":"Samuel","year":"2012","journal-title":"Cell"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1017\/S0029665118002793","article-title":"Dietary fat composition: Replacement of saturated fatty acids with PUFA as a public health strategy, with an emphasis on \u03b1-linolenic acid","volume":"78","author":"Lenighan","year":"2019","journal-title":"Proc. Nutr. Soc."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"100420","DOI":"10.1016\/j.jlr.2023.100420","article-title":"Reducing saturated fat intake lowers LDL-C but increases Lp(a) levels in African Americans: The GET-READI feeding trial","volume":"64","author":"Law","year":"2023","journal-title":"J. Lipid Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/advances\/nmx007","article-title":"Practical Dietary Recommendations for the Prevention and Management of Nonalcoholic Fatty Liver Disease in Adults","volume":"9","author":"George","year":"2018","journal-title":"Adv. Nutr."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.2337\/dc06-2220","article-title":"Monounsaturated fat-rich diet prevents central body fat distribution and decreases postprandial adiponectin expression induced by a carbohydrate-rich diet in insulin-resistant subjects","volume":"30","author":"Paniagua","year":"2007","journal-title":"Diabetes Care"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e000871","DOI":"10.1136\/bmjdrc-2019-000871","article-title":"Hepatic de novo lipogenesis is suppressed and fat oxidation is increased by omega-3 fatty acids at the expense of glucose metabolism","volume":"8","author":"Green","year":"2020","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3390\/nu2030355","article-title":"Omega-3 fatty acids and inflammatory processes","volume":"2","author":"Calder","year":"2010","journal-title":"Nutrients"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/hep.21763","article-title":"A lipidomic analysis of nonalcoholic fatty liver disease","volume":"46","author":"Puri","year":"2007","journal-title":"Hepatology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.mam.2018.03.001","article-title":"Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action","volume":"64","author":"Scorletti","year":"2018","journal-title":"Mol. Asp. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.cell.2010.07.041","article-title":"GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects","volume":"142","author":"Oh","year":"2010","journal-title":"Cell"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/j.gastro.2014.04.046","article-title":"No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial","volume":"147","author":"Sanyal","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/MEG.0000000000002297","article-title":"Efficacy of omega-3-rich Camelina sativa on the metabolic and clinical markers in nonalcoholic fatty liver disease: A randomized, controlled trial","volume":"34","author":"Musazadeh","year":"2022","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.cct.2014.02.002","article-title":"Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chain omega-3 fatty treatment in non-alcoholic fatty liver disease","volume":"37","author":"Scorletti","year":"2014","journal-title":"Contemp. Clin. Trials"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Nobili, V., Carpino, G., Alisi, A., De Vito, R., Franchitto, A., Alpini, G., Onori, P., and Gaudio, E. (2014). Role of docosahexaenoic acid treatment in improving liver histology in pediatric nonalcoholic fatty liver disease. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0088005"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.clnu.2015.05.001","article-title":"Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial","volume":"35","author":"Nogueira","year":"2016","journal-title":"Clin. Nutr."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Antraco, V.J., Hirata, B.K.S., de Jesus Sim\u00e3o, J., Cruz, M.M., da Silva, V.S., da Cunha de S\u00e1, R.D.C., Abdala, F.M., Armelin-Correa, L., and Alonso-Vale, M.I.C. (2021). Omega-3 Polyunsaturated Fatty Acids Prevent Nonalcoholic Steatohepatitis (NASH) and Stimulate Adipogenesis. Nutrients, 13.","DOI":"10.3390\/nu13020622"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Suzuki-Kemuriyama, N., Matsuzaka, T., Kuba, M., Ohno, H., Han, S.-i., Takeuchi, Y., Isaka, M., Kobayashi, K., Iwasaki, H., and Yatoh, S. (2016). Different Effects of Eicosapentaenoic and Docosahexaenoic Acids on Atherogenic High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0157580"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3945\/jn.112.171322","article-title":"Docosahexaenoic acid attenuates hepatic inflammation, oxidative stress, and fibrosis without decreasing hepatosteatosis in a Ldlr(-\/-) mouse model of western diet-induced nonalcoholic steatohepatitis","volume":"143","author":"Depner","year":"2013","journal-title":"J. Nutr."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1194\/jlr.M061275","article-title":"Docosahexaenoic acid attenuates Western diet-induced hepatic fibrosis in Ldlr-\/- mice by targeting the TGF\u03b2-Smad3 pathway","volume":"56","author":"Lytle","year":"2015","journal-title":"J. Lipid Res."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Lytle, K.A., and Jump, D.B. (2016). Is Western Diet-Induced Nonalcoholic Steatohepatitis in Ldlr-\/- Mice Reversible?. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0146942"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e18367","DOI":"10.15252\/emmm.202318367","article-title":"Multi-omic network analysis identified betacellulin as a novel target of omega-3 fatty acid attenuation of western diet-induced nonalcoholic steatohepatitis","volume":"15","author":"Padiadpu","year":"2023","journal-title":"EMBO Mol. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s13197-010-0225-8","article-title":"Trans fats-sources, health risks and alternative approach\u2014A review","volume":"48","author":"Dhaka","year":"2011","journal-title":"J. Food Sci. Technol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1038\/sj.ejcn.1602973","article-title":"Health effects of trans-fatty acids: Experimental and observational evidence","volume":"63","author":"Mozaffarian","year":"2009","journal-title":"Eur. J. Clin. Nutr."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrendo.2009.79","article-title":"Trans fatty acids: Effects on metabolic syndrome, heart disease and diabetes","volume":"5","author":"Micha","year":"2009","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"G987","DOI":"10.1152\/ajpgi.90272.2008","article-title":"Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent","volume":"295","author":"Tetri","year":"2008","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_40","first-page":"130","article-title":"Trans fatty acid intake increases likelihood of dyslipidemia especially among individuals with higher saturated fat consumption","volume":"23","author":"Magriplis","year":"2022","journal-title":"RCM"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1007\/s10620-016-4054-0","article-title":"Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease","volume":"61","author":"Softic","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Geidl-Flueck, B., and Gerber, P.A. (2017). Insights into the Hexose Liver Metabolism-Glucose versus Fructose. Nutrients, 9.","DOI":"10.3390\/nu9091026"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1172\/JCI37385","article-title":"Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight\/obese humans","volume":"119","author":"Stanhope","year":"2009","journal-title":"J. Clin. Investig."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1172\/JCI96702","article-title":"Fructose metabolism and metabolic disease","volume":"128","author":"Hannou","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jhep.2018.01.019","article-title":"Fructose and sugar: A major mediator of non-alcoholic fatty liver disease","volume":"68","author":"Jensen","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1001\/jama.2018.20579","article-title":"Effect of a Low Free Sugar Diet vs Usual Diet on Nonalcoholic Fatty Liver Disease in Adolescent Boys: A Randomized Clinical Trial","volume":"321","author":"Schwimmer","year":"2019","journal-title":"JAMA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/ejcn.2014.8","article-title":"Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of controlled feeding trials","volume":"68","author":"Chiu","year":"2014","journal-title":"Eur. J. Clin. Nutr."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Roeb, E., and Weiskirchen, R. (2021). Fructose and Non-Alcoholic Steatohepatitis. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.634344"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Federico, A., Rosato, V., Masarone, M., Torre, P., Dallio, M., Romeo, M., and Persico, M. (2021). The Role of Fructose in Non-Alcoholic Steatohepatitis: Old Relationship and New Insights. Nutrients, 13.","DOI":"10.3390\/nu13041314"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Inci, M.K., Park, S.H., Helsley, R.N., Attia, S.L., and Softic, S. (2023). Fructose impairs fat oxidation: Implications for the mechanism of western diet-induced NAFLD. J. Nutr. Biochem., 114.","DOI":"10.1016\/j.jnutbio.2022.109224"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Lanaspa, M.A., Sanchez-Lozada, L.G., Cicerchi, C., Li, N., Roncal-Jimenez, C.A., Ishimoto, T., Le, M., Garcia, G.E., Thomas, J.B., and Rivard, C.J. (2012). Uric acid stimulates fructokinase and accelerates fructose metabolism in the development of fatty liver. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0047948"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.bbrc.2009.09.109","article-title":"Replacing dietary glucose with fructose increases ChREBP activity and SREBP-1 protein in rat liver nucleus","volume":"390","author":"Koo","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI81993","article-title":"ChREBP regulates fructose-induced glucose production independently of insulin signaling","volume":"126","author":"Kim","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1172\/JCI94585","article-title":"Divergent effects of glucose and fructose on hepatic lipogenesis and insulin signaling","volume":"127","author":"Softic","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Jeong, M.K., Min, B.H., Choi, Y.R., Hyun, J.Y., Park, H.J., Eom, J.A., Won, S.M., Jeong, J.J., Oh, K.K., and Gupta, H. (2022). Food and Gut Microbiota-Derived Metabolites in Nonalcoholic Fatty Liver Disease. Foods, 11.","DOI":"10.3390\/foods11172703"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/s42255-020-0261-2","article-title":"Fructose stimulated de novo lipogenesis is promoted by inflammation","volume":"2","author":"Todoric","year":"2020","journal-title":"Nat. Metab."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/1440-1681.12241","article-title":"Toll-like receptor-4 signalling in the progression of non-alcoholic fatty liver disease induced by high-fat and high-fructose diet in mice","volume":"41","author":"Liu","year":"2014","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.3748\/wjg.v18.i19.2300","article-title":"Animal models of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"18","author":"Takahashi","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.3945\/jn.109.105858","article-title":"Rats Fed Fructose-Enriched Diets Have Characteristics of Nonalcoholic Hepatic Steatosis","volume":"139","author":"Kawasaki","year":"2009","journal-title":"J. Nutr."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Bhat, N., and Mani, A. (2023). Dysregulation of Lipid and Glucose Metabolism in Nonalcoholic Fatty Liver Disease. Nutrients, 15.","DOI":"10.3390\/nu15102323"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Takahashi, Y., Sugimoto, K., Soejima, Y., Kumagai, A., Koeda, T., Shojo, A., Nakagawa, K., Harada, N., Yamaji, R., and Inui, H. (2015). Inhibitory Effects of Eucalyptus and Banaba Leaf Extracts on Nonalcoholic Steatohepatitis Induced by a High-Fructose\/High-Glucose Diet in Rats. BioMed Res. Int., 2015.","DOI":"10.1155\/2015\/296207"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3109\/10408363.2015.1084990","article-title":"Sugar consumption, metabolic disease and obesity: The state of the controversy","volume":"53","author":"Stanhope","year":"2016","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jhep.2015.05.021","article-title":"Sugar sweetened beverages and fatty liver disease: Rising concern and call to action","volume":"63","author":"Abdelmalek","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3945\/ajcn.111.022533","article-title":"Sucrose-sweetened beverages increase fat storage in the liver, muscle, and visceral fat depot: A 6-mo randomized intervention study","volume":"95","author":"Maersk","year":"2012","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S1665-2681(19)30931-7","article-title":"High coffee intake is associated with lower grade nonalcoholic fatty liver disease: The role of peripheral antioxidant activity","volume":"11","author":"Uribe","year":"2012","journal-title":"Ann. Hepatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1017\/jns.2019.10","article-title":"Coffee prevents fatty liver disease induced by a high-fat diet by modulating pathways of the gut-liver axis","volume":"8","author":"Vitaglione","year":"2019","journal-title":"J. Nutr. Sci."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Kennedy, O.J., Fallowfield, J.A., Poole, R., Hayes, P.C., Parkes, J., and Roderick, P.J. (2021). All coffee types decrease the risk of adverse clinical outcomes in chronic liver disease: A UK Biobank study. BMC Public Health, 21.","DOI":"10.1186\/s12889-021-10991-7"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.clnu.2016.03.012","article-title":"Coffee and tea consumption in relation with non-alcoholic fatty liver and metabolic syndrome: A systematic review and meta-analysis of observational studies","volume":"35","author":"Marventano","year":"2016","journal-title":"Clin. Nutr."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Coelho, M., Patarr\u00e3o, R.S., Sousa-Lima, I., Ribeiro, R.T., Meneses, M.J., Andrade, R., Mendes, V.M., Manadas, B., Raposo, J.F., and Macedo, M.P. (2022). Increased Intake of Both Caffeine and Non-Caffeine Coffee Components Is Associated with Reduced NAFLD Severity in Subjects with Type 2 Diabetes. Nutrients, 15.","DOI":"10.3390\/nu15010004"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12937-021-00694-5","article-title":"Effects of supplementation with main coffee components including caffeine and\/or chlorogenic acid on hepatic, metabolic, and inflammatory indices in patients with non-alcoholic fatty liver disease and type 2 diabetes: A randomized, double-blind, placebo-controlled, clinical trial","volume":"20","author":"Mansour","year":"2021","journal-title":"Nutr. J."},{"key":"ref_71","first-page":"241","article-title":"Short-term effects of coffee components consumption on gut microbiota in patients with non-alcoholic fatty liver and diabetes: A pilot randomized placebo-controlled clinical trial","volume":"19","author":"Mansour","year":"2020","journal-title":"EXCLI J."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Shokouh, P., Jeppesen, P.B., Christiansen, C.B., Mellbye, F.B., Hermansen, K., and Gregersen, S. (2019). Efficacy of Arabica Versus Robusta Coffee in Improving Weight, Insulin Resistance, and Liver Steatosis in a Rat Model of Type-2 Diabetes. Nutrients, 11.","DOI":"10.3390\/nu11092074"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.1021\/jf904062c","article-title":"Coffee and caffeine ameliorate hyperglycemia, fatty liver, and inflammatory adipocytokine expression in spontaneously diabetic KK-Ay mice","volume":"58","author":"Yamauchi","year":"2010","journal-title":"J. Agric. Food Chem."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1039\/C5FO00247H","article-title":"Caffeine ameliorates high energy diet-induced hepatic steatosis: Sirtuin 3 acts as a bridge in the lipid metabolism pathway","volume":"6","author":"Zhang","year":"2015","journal-title":"Food Funct."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.bcp.2019.04.018","article-title":"Telmisartan and\/or chlorogenic acid attenuates fructose-induced non-alcoholic fatty liver disease in rats: Implications of cross-talk between angiotensin, the sphingosine kinase\/sphingoine-1-phosphate pathway, and TLR4 receptors","volume":"164","author":"Alqarni","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Xin, X., Chen, C., Xu, X., Lv, S., Sun, Q., An, Z., Chen, Y., Xiong, Z., Hu, Y., and Feng, Q. (2025). Caffeine ameliorates metabolic-associated steatohepatitis by rescuing hepatic Dusp9. Redox Biol., 80.","DOI":"10.1016\/j.redox.2025.103499"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Vel\u00e1zquez, A.M., Roglans, N., Bentanachs, R., Gen\u00e9, M., Sala-Vila, A., L\u00e1zaro, I., Rodr\u00edguez-Morat\u00f3, J., S\u00e1nchez, R.M., Laguna, J.C., and Alegret, M. (2020). Effects of a Low Dose of Caffeine Alone or as Part of a Green Coffee Extract, in a Rat Dietary Model of Lean Non-Alcoholic Fatty Liver Disease without Inflammation. Nutrients, 12.","DOI":"10.3390\/nu12113240"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"7489","DOI":"10.1039\/C9FO00502A","article-title":"Collaborative effects of chlorogenic acid and caffeine on lipid metabolism via the AMPK\u03b1-LXR\u03b1\/SREBP-1c pathway in high-fat diet-induced obese mice","volume":"10","author":"Xu","year":"2019","journal-title":"Food Funct."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Yang, F., Luo, L., Zhu, Z.D., Zhou, X., Wang, Y., Xue, J., Zhang, J., Cai, X., Chen, Z.L., and Ma, Q. (2017). Chlorogenic Acid Inhibits Liver Fibrosis by Blocking the miR-21-Regulated TGF-\u03b21\/Smad7 Signaling Pathway in Vitro and in Vivo. Front. Pharmacol., 8.","DOI":"10.3389\/fphar.2017.00929"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Salvoza, N., Giraudi, P.J., Tiribelli, C., and Rosso, N. (2022). Natural Compounds for Counteracting Nonalcoholic Fatty Liver Disease (NAFLD): Advantages and Limitations of the Suggested Candidates. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23052764"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Dungubat, E., Watabe, S., Togashi-Kumagai, A., Watanabe, M., Kobayashi, Y., Harada, N., Yamaji, R., Fukusato, T., Lodon, G., and Sevjid, B. (2020). Effects of Caffeine and Chlorogenic Acid on Nonalcoholic Steatohepatitis in Mice Induced by Choline-Deficient, L-Amino Acid-Defined, High-Fat Diet. Nutrients, 12.","DOI":"10.3390\/nu12123886"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.tox.2019.02.008","article-title":"Prenatal caffeine exposure increases the susceptibility to non-alcoholic fatty liver disease in female offspring rats via activation of GR-C\/EBP\u03b1-SIRT1 pathway","volume":"417","author":"Hu","year":"2019","journal-title":"Toxicology"},{"key":"ref_83","first-page":"e50118","article-title":"The Influence of Coffee on Reducing Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes: A Review","volume":"15","author":"Kaur","year":"2023","journal-title":"Cureus"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1021\/jf400920x","article-title":"Supplementation of a high-fat diet with chlorogenic acid is associated with insulin resistance and hepatic lipid accumulation in mice","volume":"61","author":"Mubarak","year":"2013","journal-title":"J. Agric. Food Chem."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1089\/met.2016.0114","article-title":"Daily Coffee Intake Inhibits Pancreatic Beta Cell Damage and Nonalcoholic Steatohepatitis in a Mouse Model of Spontaneous Metabolic Syndrome, Tsumura-Suzuki Obese Diabetic Mice","volume":"15","author":"Watanabe","year":"2017","journal-title":"Metab. Syndr. Relat. Disord."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Li, Z.D., Geng, M.Y., Dou, S.R., Wang, X., Zhang, Z.H., and Chang, Y.Z. (2022). Caffeine Decreases Hepcidin Expression to Alleviate Aberrant Iron Metabolism under Inflammation by Regulating the IL-6\/STAT3 Pathway. Life, 12.","DOI":"10.3390\/life12071025"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.3892\/etm.2016.3136","article-title":"Chlorogenic acid induces apoptosis to inhibit inflammatory proliferation of IL-6-induced fibroblast-like synoviocytes through modulating the activation of JAK\/STAT and NF-\u03baB signaling pathways","volume":"11","author":"Lou","year":"2016","journal-title":"Exp. Ther. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.cgh.2018.01.026","article-title":"Among Patients With Nonalcoholic Fatty Liver Disease, Modest Alcohol Use Is Associated With Less Improvement in Histologic Steatosis and Steatohepatitis","volume":"16","author":"Ajmera","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41572-018-0014-7","article-title":"Alcoholic liver disease","volume":"4","author":"Seitz","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.cld.2012.08.002","article-title":"Alcohol metabolism","volume":"16","author":"Cederbaum","year":"2012","journal-title":"Clin. Liver Dis."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1530-0277.2008.00827.x","article-title":"Molecular mechanisms of alcoholic fatty liver","volume":"33","author":"Purohit","year":"2009","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/apt.17388","article-title":"Meta-analysis: The impact of light-to-moderate alcohol consumption on progressive non-alcoholic fatty liver disease","volume":"57","author":"Magherman","year":"2023","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"70","DOI":"10.21037\/tgh.2019.09.02","article-title":"Effect of alcohol consumption on nonalcoholic fatty liver disease","volume":"4","author":"Weng","year":"2019","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.jhep.2012.03.024","article-title":"Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD)","volume":"57","author":"Dunn","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1002\/hep.22292","article-title":"Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease","volume":"47","author":"Dunn","year":"2008","journal-title":"Hepatology"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1038\/ajg.2009.361","article-title":"Light and moderate alcohol consumption significantly reduces the prevalence of fatty liver in the Japanese male population","volume":"104","author":"Gunji","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1365-2036.2010.04520.x","article-title":"Alcohol consumption appears to protect against non-alcoholic fatty liver disease","volume":"33","author":"Moriya","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jhep.2014.11.025","article-title":"Roles of alcohol consumption in fatty liver: A longitudinal study","volume":"62","author":"Moriya","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1097\/MEG.0b013e328328f3ec","article-title":"Effects of light-to-moderate alcohol consumption on steatosis and steatohepatitis in severely obese patients","volume":"21","author":"Cotrim","year":"2009","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"7927685","DOI":"10.1155\/2017\/7927685","article-title":"Alcohol Consumption in Diabetic Patients with Nonalcoholic Fatty Liver Disease","volume":"2017","author":"Patel","year":"2017","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Sogabe, M., Okahisa, T., Nakagawa, T., Fukuno, H., Nakasono, M., Tomonari, T., Tanaka, T., Tanaka, H., Taniguchi, T., and Muguruma, N. (2016). Influence of light alcohol consumption on lifestyle-related diseases: A predictor of fatty liver with liver enzyme elevation in Japanese females with metabolic syndrome. BMC Gastroenterol., 16.","DOI":"10.1186\/s12876-016-0431-6"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.jhep.2010.12.034","article-title":"Synergistic steatohepatitis by moderate obesity and alcohol in mice despite increased adiponectin and p-AMPK","volume":"55","author":"Xu","year":"2011","journal-title":"J. Hepatol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jhep.2012.09.016","article-title":"Activation of toll-like receptor 3 attenuates alcoholic liver injury by stimulating Kupffer cells and stellate cells to produce interleukin-10 in mice","volume":"58","author":"Byun","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1038\/nutd.2015.4","article-title":"Effect of multiple binge alcohol on diet-induced liver injury in a mouse model of obesity","volume":"5","author":"Duly","year":"2015","journal-title":"Nutr. Diabetes"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.alcohol.2020.04.004","article-title":"Effects of low ethanol consumption on nonalcoholic steatohepatitis in mice","volume":"87","author":"Takahashi","year":"2020","journal-title":"Alcohol"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"G410","DOI":"10.1152\/ajpgi.00066.2019","article-title":"Addition of trans fat and alcohol has divergent effects on atherogenic diet-induced liver injury in rodent models of steatohepatitis","volume":"318","author":"Daniels","year":"2020","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e00174","DOI":"10.1097\/HC9.0000000000000174","article-title":"Single ethanol binge causes severe liver injury in mice fed Western diet","volume":"7","author":"Yeh","year":"2023","journal-title":"Hepatol. Commun."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/ajg.2012.20","article-title":"What should we recommend to our patients with NAFLD regarding alcohol use?","volume":"107","author":"Liangpunsakul","year":"2012","journal-title":"Am. J. Gastroenterol."},{"key":"ref_109","unstructured":"World Health Organization (2018). Global Status Report on Alcohol and Health 2018, World Health Organization."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1872-034X.2007.00215.x","article-title":"Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis","volume":"38","author":"Stefano","year":"2008","journal-title":"Hepatol. Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1142\/S0192415X18500325","article-title":"Epigallocatechin-3-Gallate-Rich Green Tea Extract Ameliorates Fatty Liver and Weight Gain in Mice Fed a High Fat Diet by Activating the Sirtuin 1 and AMP Activating Protein Kinase Pathway","volume":"46","author":"Bae","year":"2018","journal-title":"Am. J. Chin. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.jnutbio.2015.07.002","article-title":"Decaffeinated green tea extract rich in epigallocatechin-3-gallate prevents fatty liver disease by increased activities of mitochondrial respiratory chain complexes in diet-induced obesity mice","volume":"26","author":"Santamarina","year":"2015","journal-title":"J. Nutr. Biochem."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Santamarina, A.B., Oliveira, J.L., Silva, F.P., Carnier, J., Mennitti, L.V., Santana, A.A., de Souza, G.H., Ribeiro, E.B., Oller do Nascimento, C.M., and Lira, F.S. (2015). Green Tea Extract Rich in Epigallocatechin-3-Gallate Prevents Fatty Liver by AMPK Activation via LKB1 in Mice Fed a High-Fat Diet. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0141227"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ejphar.2015.05.005","article-title":"Epigallocatechin gallate attenuated non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet","volume":"761","author":"Ding","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1700696","DOI":"10.1002\/mnfr.201700696","article-title":"Green Tea Polyphenol EGCG Alleviates Metabolic Abnormality and Fatty Liver by Decreasing Bile Acid and Lipid Absorption in Mice","volume":"62","author":"Huang","year":"2018","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00394-013-0516-8","article-title":"Epigallocatechin gallate attenuates fibrosis, oxidative stress, and inflammation in non-alcoholic fatty liver disease rat model through TGF\/SMAD, PI3 K\/Akt\/FoxO1, and NF-kappa B pathways","volume":"53","author":"Xiao","year":"2014","journal-title":"Eur. J. Nutr."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"28","DOI":"10.4103\/2008-7802.173051","article-title":"The Effect of Green Tea Extract Supplementation on Liver Enzymes in Patients with Nonalcoholic Fatty Liver Disease","volume":"7","author":"Pezeshki","year":"2016","journal-title":"Int. J. Prev. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/ptr.6826","article-title":"Effect of sour tea supplementation on liver enzymes, lipid profile, blood pressure, and antioxidant status in patients with non-alcoholic fatty liver disease: A double-blind randomized controlled clinical trial","volume":"35","author":"Izadi","year":"2021","journal-title":"Phytother. Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3892\/ijmm.2013.1503","article-title":"Green tea with high-density catechins improves liver function and fat infiltration in non-alcoholic fatty liver disease (NAFLD) patients: A double-blind placebo-controlled study","volume":"32","author":"Sakata","year":"2013","journal-title":"Int. J. Mol. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"100131","DOI":"10.1016\/j.iliver.2024.100131","article-title":"New approaches to the treatment of metabolic dysfunction-associated steatotic liver with natural products","volume":"3","author":"Yadav","year":"2024","journal-title":"iLIVER"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Li, Y., Deng, X., Tan, X., Li, Q., Yu, Z., Wu, W., Ma, X., Zeng, J., and Wang, X. (2024). Protective role of curcumin in disease progression from non-alcoholic fatty liver disease to hepatocellular carcinoma: A meta-analysis. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1343193"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Shao, W., Yu, Z., Chiang, Y., Yang, Y., Chai, T., Foltz, W., Lu, H., Fantus, I.G., and Jin, T. (2012). Curcumin prevents high fat diet induced insulin resistance and obesity via attenuating lipogenesis in liver and inflammatory pathway in adipocytes. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0028784"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Guo, J., Li, Z., Yao, Y., Fang, L., Yu, M., and Wang, Z. (2024). Curcumin in the treatment of inflammation and oxidative stress responses in traumatic brain injury: A systematic review and meta-analysis. Front. Neurol., 15.","DOI":"10.3389\/fneur.2024.1380353"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2467479","DOI":"10.1080\/16583655.2025.2467479","article-title":"Mechanistic insights into curcumin\u2019s role in modulating autophagy and redox imbalance in experimentally induced MASH","volume":"19","author":"Elkordy","year":"2025","journal-title":"J. Taibah Univ. Sci."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3892\/etm.2016.2969","article-title":"Curcumin suppresses transforming growth factor-\u03b21-induced cardiac fibroblast differentiation via inhibition of Smad-2 and p38 MAPK signaling pathways","volume":"11","author":"Liu","year":"2016","journal-title":"Exp. Ther. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1080\/15376516.2020.1801926","article-title":"Combination of pomegranate extract and curcumin ameliorates thioacetamide-induced liver fibrosis in rats: Impact on TGF-\u03b2\/Smad3 and NF-\u03baB signaling pathways","volume":"30","author":"Gowifel","year":"2020","journal-title":"Toxicol. Mech. Methods"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1024\/0300-9831\/a000629","article-title":"Efficacy of phytosomal curcumin among patients with non-alcoholic fatty liver disease","volume":"91","author":"Mirhafez","year":"2021","journal-title":"Int. J. Vitam. Nutr. Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00394-019-01916-7","article-title":"Effects of phytosomal curcumin on anthropometric parameters, insulin resistance, cortisolemia and non-alcoholic fatty liver disease indices: A double-blind, placebo-controlled clinical trial","volume":"59","author":"Cicero","year":"2020","journal-title":"Eur. J. Nutr."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Rahimlou, M., Baghdadi, G., Khodi, A., Rahimi, Z., Saki, N., Banaei Jahromi, N., Cheraghian, B., Tavasolian, R., and Hosseini, S.A. (2024). Polyphenol consumption and Nonalcoholic fatty liver disease risk in adults. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-57416-0"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Saadati, S., Sadeghi, A., Mansour, A., Yari, Z., Poustchi, H., Hedayati, M., Hatami, B., and Hekmatdoost, A. (2019). Curcumin and inflammation in non-alcoholic fatty liver disease: A randomized, placebo controlled clinical trial. BMC Gastroenterol., 19.","DOI":"10.1186\/s12876-019-1055-4"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Obrzut, O., Gosty\u0144ska-Stawna, A., Kustrzy\u0144ska, K., Stawny, M., and Krajka-Ku\u017aniak, V. (2025). Curcumin: A Natural Warrior Against Inflammatory Liver Diseases. Nutrients, 17.","DOI":"10.3390\/nu17081373"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"10010","DOI":"10.1002\/fsn3.4595","article-title":"The Effectiveness of Curcumin, Resveratrol, and Silymarin on MASLD: A Systematic Review and Meta-Analysis","volume":"12","author":"Huang","year":"2024","journal-title":"Food Sci. Nutr."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.cmet.2011.10.002","article-title":"Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans","volume":"14","author":"Timmers","year":"2011","journal-title":"Cell Metab."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3109\/00365521.2015.1107620","article-title":"Placebo-controlled, randomised clinical trial: High-dose resveratrol treatment for non-alcoholic fatty liver disease","volume":"51","author":"Kreuzfeldt","year":"2016","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Cicero, A.F.G., Colletti, A., and Bellentani, S. (2018). Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence. Nutrients, 10.","DOI":"10.3390\/nu10091153"},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Kasprzak-Drozd, K., Nizi\u0144ski, P., Kasprzak, P., Kondracka, A., Oniszczuk, T., Rusinek, A., and Oniszczuk, A. (2024). Does Resveratrol Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)?. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25073746"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Yang, Y., and Wang, X. (2024). Nano-drug delivery systems (NDDS) in metabolic dysfunction-associated steatotic liver disease (MASLD): Current status, prospects and challenges. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1419384"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"155947","DOI":"10.1016\/j.phymed.2024.155947","article-title":"Silymarin targets the FXR protein through microbial metabolite 7-keto-deoxycholic acid to treat MASLD in obese mice","volume":"133","author":"Yi","year":"2024","journal-title":"Phytomedicine"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.cgh.2017.04.016","article-title":"A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis","volume":"15","author":"Mahadeva","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12944-024-02220-y","article-title":"Silymarin decreases liver stiffness associated with gut microbiota in patients with metabolic dysfunction-associated steatotic liver disease: A randomized, double-blind, placebo-controlled trial","volume":"23","author":"Jin","year":"2024","journal-title":"Lipids Health Dis."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"e9061","DOI":"10.1097\/MD.0000000000009061","article-title":"The therapeutic effect of silymarin in the treatment of nonalcoholic fatty disease: A meta-analysis (PRISMA) of randomized control trials","volume":"96","author":"Zhong","year":"2017","journal-title":"Medicine"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1002\/ptr.6171","article-title":"Milk thistle (Silybum marianum): A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases","volume":"32","author":"Abenavoli","year":"2018","journal-title":"Phytother. Res."},{"key":"ref_143","first-page":"9","article-title":"Sylimarin Versus Essential Phospholipids in Metabolic Associated Steatotic Liver Disease (MASLD)\u2014A Prospective Comparative Randomized Trial","volume":"19","author":"Manuc","year":"2024","journal-title":"Maedica"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"7523","DOI":"10.1002\/fsn3.3729","article-title":"A narrative review on the role of hesperidin on metabolic parameters, liver enzymes, and inflammatory markers in nonalcoholic fatty liver disease","volume":"11","author":"Morshedzadeh","year":"2023","journal-title":"Food Sci. Nutr."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Sivaslioglu, A., and Goktas, Z. (2024). A comprehensive review on the impact of hesperidin and its aglycone hesperetin on metabolic dysfunction-associated steatotic liver disease and other liver disorders. Nutr. Res. Rev., 1\u201313.","DOI":"10.1017\/S0954422424000350"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1089\/jmf.2023.K.0259","article-title":"Hesperidin Protects Against High-Fat Diet-Induced Lipotoxicity in Rats by Inhibiting Pyroptosis","volume":"27","author":"Luo","year":"2024","journal-title":"J. Med. Food"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1039\/D3FO04348G","article-title":"The promotion of fatty acid \u03b2-oxidation by hesperidin via activating SIRT1\/PGC1\u03b1 to improve NAFLD induced by a high-fat diet","volume":"15","author":"Nie","year":"2024","journal-title":"Food Funct."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.18632\/aging.203817","article-title":"Hesperidin suppresses ERS-induced inflammation in the pathogenesis of non-alcoholic fatty liver disease","volume":"14","author":"Xie","year":"2022","journal-title":"Aging"},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Chen, S., Lu, H., Yin, G., Zhang, X., Meng, D., Yu, W., Wang, L., Liu, H., and Zhang, F. (2025). Hesperitin prevents non-alcoholic steatohepatitis by modulating mitochondrial dynamics and mitophagy via the AMPK\u03b1-Drp1\/PINK1-Parkin signaling pathway. Biochim. Biophys. Acta Mol. Cell Biol. Lipids, 1870.","DOI":"10.1016\/j.bbalip.2024.159570"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1002\/ptr.6406","article-title":"Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo-controlled, double-blind clinical trial","volume":"33","author":"Cheraghpour","year":"2019","journal-title":"Phytother. Res."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41430-020-0679-3","article-title":"The efficacy of flaxseed and hesperidin on non-alcoholic fatty liver disease: An open-labeled randomized controlled trial","volume":"75","author":"Yari","year":"2021","journal-title":"Eur. J. Clin. Nutr."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Liu, B., Jiang, X., Cai, L., Zhao, X., Dai, Z., Wu, G., and Li, X. (2019). Putrescine mitigates intestinal atrophy through suppressing inflammatory response in weanling piglets. J. Anim. Sci. Biotechnol., 10.","DOI":"10.1186\/s40104-019-0379-9"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3181\/00379727-194-43100","article-title":"Effect of dietary putrescine on whole body growth and polyamine metabolism","volume":"194","author":"Smith","year":"1990","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Kasahara, N., Teratani, T., Yokota, S., Sakuma, Y., Sasanuma, H., Fujimoto, Y., Ijichi, T., Urahashi, T., Yoshitomi, H., and Kitayama, J. (2024). Dietary polyamines promote intestinal adaptation in an experimental model of short bowel syndrome. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-55258-4"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1556\/2060.2022.00138","article-title":"Effects of putrescine on oxidative stress, spermidine\/spermine-N(1)-acetyltransferase, inflammation and energy levels in liver and serum in rats with brain ischemia-reperfusion","volume":"110","author":"Dasdelen","year":"2023","journal-title":"Physiol. Int."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/path.6330","article-title":"Increased hepatic putrescine levels as a new potential factor related to the progression of metabolic dysfunction-associated steatotic liver disease","volume":"264","author":"Lambertos","year":"2024","journal-title":"J. Pathol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"eaan2788","DOI":"10.1126\/science.aan2788","article-title":"Spermidine in health and disease","volume":"359","author":"Madeo","year":"2018","journal-title":"Science"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/hep.30616","article-title":"Spermidine Confers Liver Protection by Enhancing NRF2 Signaling Through a MAP1S-Mediated Noncanonical Mechanism","volume":"70","author":"Liu","year":"2019","journal-title":"Hepatology"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.bbrc.2018.09.078","article-title":"Spermidine ameliorates non-alcoholic fatty liver disease through regulating lipid metabolism via AMPK","volume":"505","author":"Gao","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Zhou, S., Gu, J., Liu, R., Wei, S., Wang, Q., Shen, H., Dai, Y., Zhou, H., Zhang, F., and Lu, L. (2018). Spermine Alleviates Acute Liver Injury by Inhibiting Liver-Resident Macrophage Pro-Inflammatory Response Through ATG5-Dependent Autophagy. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.00948"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"11054","DOI":"10.1039\/C8RA05421E","article-title":"Effects of spermine on liver barrier function, amino acid transporters, immune status, and apoptosis in piglets","volume":"9","author":"Liu","year":"2019","journal-title":"RSC Adv."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.2147\/DMSO.S247844","article-title":"Kukoamine B Ameliorate Insulin Resistance, Oxidative Stress, Inflammation and Other Metabolic Abnormalities in High-Fat\/High-Fructose-Fed Rats","volume":"13","author":"Zhao","year":"2020","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.biopha.2017.02.024","article-title":"Kukoamine A attenuates insulin resistance and fatty liver through downregulation of Srebp-1c","volume":"89","author":"Li","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Barchetta, I., Angelico, F., Del Ben, M., Baroni, M.G., Pozzilli, P., Morini, S., and Cavallo, M.G. (2011). Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. BMC Med., 9.","DOI":"10.1186\/1741-7015-9-85"},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Barchetta, I., Del Ben, M., Angelico, F., Di Martino, M., Fraioli, A., La Torre, G., Saulle, R., Perri, L., Morini, S., and Tiberti, C. (2016). No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial. BMC Med., 14.","DOI":"10.1186\/s12916-016-0638-y"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"901","DOI":"10.4254\/wjh.v6.i12.901","article-title":"Vitamin D deficiency in chronic liver disease","volume":"6","author":"Iruzubieta","year":"2014","journal-title":"World J. Hepatol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/archdischild-2014-307961","article-title":"What diseases are causally linked to vitamin D deficiency?","volume":"101","author":"Reid","year":"2016","journal-title":"Arch. Dis. Child."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.3748\/wjg.v21.i6.1718","article-title":"Vitamin D: A new player in non-alcoholic fatty liver disease?","volume":"21","author":"Eliades","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00125-011-2446-4","article-title":"Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of randomised trials","volume":"55","author":"Musso","year":"2012","journal-title":"Diabetologia"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s12020-014-0336-5","article-title":"Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial","volume":"47","author":"Sharifi","year":"2014","journal-title":"Endocrine"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.dsx.2018.03.006","article-title":"Vitamin D supplementation for the treatment of non-alcoholic fatty liver disease: A randomized double blind placebo controlled trial","volume":"12","author":"Dabbaghmanesh","year":"2018","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"119550","DOI":"10.1016\/j.lfs.2021.119550","article-title":"Vitamin D supplementation decreases visceral adiposity and normalizes leptinemia and circulating TNF-\u03b1 levels in western diet-fed obese rats","volume":"278","author":"Cordeiro","year":"2021","journal-title":"Life Sci."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.biopha.2018.10.140","article-title":"Vitamin D and liver fibrosis: Molecular mechanisms and clinical studies","volume":"109","author":"Udomsinprasert","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"847849","DOI":"10.1155\/2012\/847849","article-title":"MicroRNA Regulation of Cholesterol Metabolism","volume":"2012","author":"Rotllan","year":"2012","journal-title":"Cholesterol"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1111\/jgh.16723","article-title":"Vitamin E improves serum markers and histology in adults with metabolic dysfunction-associated steatotic liver disease: Systematic review and meta-analysis","volume":"39","author":"Chee","year":"2024","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.cct.2008.09.003","article-title":"Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design","volume":"30","author":"Chalasani","year":"2009","journal-title":"Contemp. Clin. Trials"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.3748\/wjg.v21.i13.3777","article-title":"Current pharmacological therapies for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"21","author":"Takahashi","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7326\/0003-4819-142-1-200501040-00110","article-title":"Meta-analysis: High-dosage vitamin E supplementation may increase all-cause mortality","volume":"142","author":"Miller","year":"2005","journal-title":"Ann. Intern. Med."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1475-2891-2-9","article-title":"Vitamin C and Vitamin E in Prevention of Nonalcoholic Fatty Liver Disease (NAFLD) in Choline Deficient Diet Fed Rats","volume":"2","author":"Oliveira","year":"2003","journal-title":"Nutr. J."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1322s","DOI":"10.1093\/ajcn\/62.6.1322S","article-title":"Interaction among vitamin C, vitamin E, and beta-carotene","volume":"62","author":"Niki","year":"1995","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"He, Z., Li, X., Yang, H., Wu, P., Wang, S., Cao, D., Guo, X., Xu, Z., Gao, J., and Zhang, W. (2021). Effects of Oral Vitamin C Supplementation on Liver Health and Associated Parameters in Patients With Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial. Front. Nutr., 8.","DOI":"10.3389\/fnut.2021.745609"},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Wu, H., Guo, J.L., Yao, J.J., Yu, J.J., Xia, R.Y., Huang, W.Q., Tang, X., and He, G.M. (2023). Serum vitamin C levels and risk of non-alcoholic fatty liver disease: Results from a cross-sectional study and Mendelian randomization analysis. Front. Nutr., 10.","DOI":"10.3389\/fnut.2023.1162031"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"S220","DOI":"10.3350\/cmh.2022.0360","article-title":"Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma","volume":"29","author":"Cho","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Prasad, A.S. (2014). Zinc is an Antioxidant and Anti-Inflammatory Agent: Its Role in Human Health. Front. Nutr., 1.","DOI":"10.3389\/fnut.2014.00014"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/0884533611433534","article-title":"Zinc and liver disease","volume":"27","author":"Mohammad","year":"2012","journal-title":"Nutr. Clin. Pract."},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Bolatimi, O.E., Head, K.Z., Luo, J., Gripshover, T.C., Lin, Q., Adiele, N.V., Watson, W.H., Wilkerson, C., Cai, L., and Cave, M.C. (2023). Can Zinc Supplementation Attenuate High Fat Diet-Induced Non-Alcoholic Fatty Liver Disease?. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021763"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s12011-019-02015-8","article-title":"The Effect of Zinc Supplementation on Steatosis Severity and Liver Function Enzymes in Overweight\/Obese Patients with Mild to Moderate Non-alcoholic Fatty Liver Following Calorie-Restricted Diet: A Double-Blind, Randomized Placebo-Controlled Trial","volume":"197","author":"Fathi","year":"2020","journal-title":"Biol. Trace Elem. Res."},{"key":"ref_189","doi-asserted-by":"crossref","unstructured":"Liu, Y., Qin, X., Chen, T., Chen, M., Wu, L., and He, B. (2024). Exploring the interactions between metabolic dysfunction-associated fatty liver disease and micronutrients: From molecular mechanisms to clinical applications. Front. Nutr., 11.","DOI":"10.3389\/fnut.2024.1344924"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1007\/s12011-023-03954-z","article-title":"Effects of Zinc Supplementation on Inflammatory Status and Nonalcoholic Steatohepatitis in Overweight or Obese Children: A Randomized Clinical Trial","volume":"202","author":"Ostadmohammadi","year":"2024","journal-title":"Biol. Trace Elem. Res."},{"key":"ref_191","doi-asserted-by":"crossref","unstructured":"Rezaei, S.M.A., Mohammadi, F., Eftekhari, M.H., Ejtehadi, F., Ghaem, H., and Mohammadipoor, N. (2023). The effects of zinc supplementation on the metabolic factors in patients with non-alcoholic fatty liver disease: A randomized, double-blinded, placebo-controlled clinical trial. BMC Nutr., 9.","DOI":"10.1186\/s40795-023-00776-z"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.1021\/acs.jafc.0c01103","article-title":"Zinc Supplementation Alleviates Lipid and Glucose Metabolic Disorders Induced by a High-Fat Diet","volume":"68","author":"Qi","year":"2020","journal-title":"J. Agric. Food Chem."},{"key":"ref_193","doi-asserted-by":"crossref","unstructured":"Xu, L., Lu, Y., Wang, N., and Feng, Y. (2022). The Role and Mechanisms of Selenium Supplementation on Fatty Liver-Associated Disorder. Antioxidants, 11.","DOI":"10.3390\/antiox11050922"},{"key":"ref_194","doi-asserted-by":"crossref","unstructured":"Luo, Q., Bai, X., Li, X., and Liu, C. (2025). The role and mechanism of selenium in the prevention and progression of hepatocellular carcinoma. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1557233"},{"key":"ref_195","first-page":"59","article-title":"Serum zinc level and dietary zinc intake status in non-alcoholic fatty liver disease: A meta-analysis and systematic review","volume":"1","author":"Akdas","year":"2020","journal-title":"Hepatol. Forum"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s12011-017-1059-2","article-title":"Zinc and Selenium Co-supplementation Reduces Some Lipid Peroxidation and Angiogenesis Markers in a Rat Model of NAFLD-Fed High Fat Diet","volume":"181","author":"Mousavi","year":"2018","journal-title":"Biol. Trace Elem. Res."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1007\/s12325-025-03238-z","article-title":"Dietary Intake of Major Minerals and Trace Elements in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: Implications for Dietary Intervention","volume":"42","author":"Isakov","year":"2025","journal-title":"Adv. Ther."},{"key":"ref_198","doi-asserted-by":"crossref","unstructured":"Li, J., Wan, S., Dai, X., Cui, Y., and Lu, Z. (2025). The relationship between dietary sodium intake and all-cause mortality in patients with non-alcoholic fatty liver disease: A cohort study from NHANES 2003-2018. Front. Nutr., 12.","DOI":"10.3389\/fnut.2025.1530025"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.nutres.2025.03.004","article-title":"High salt diet causally increases metabolic dysfunction-associated steatotic liver disease risk: A bidirectional mendelian randomization study","volume":"136","author":"Liu","year":"2025","journal-title":"Nutr. Res."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1002\/ptr.6410","article-title":"Natural compounds in the chemoprevention of alcoholic liver disease","volume":"33","author":"Tu","year":"2019","journal-title":"Phytother. Res."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12944-024-02031-1","article-title":"What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?","volume":"23","author":"Tarantino","year":"2024","journal-title":"Lipids Health Dis."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-020-00114-z","article-title":"Natural products in drug discovery: Advances and opportunities","volume":"20","author":"Atanasov","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_203","doi-asserted-by":"crossref","unstructured":"Heydari, M., Rauf, A., Thiruvengadam, M., Chen, X., and Hashempur, M.H. (2022). Editorial: Clinical safety of natural products, an evidence-based approach. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.960556"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"31578","DOI":"10.1039\/D3RA06831E","article-title":"Challenges in natural product-based drug discovery assisted with in silico-based methods","volume":"13","author":"Simoben","year":"2023","journal-title":"RSC Adv."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s42255-024-01043-6","article-title":"An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"6","author":"Vacca","year":"2024","journal-title":"Nat. Metab."}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/17\/13\/2211\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:03:40Z","timestamp":1760033020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/17\/13\/2211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":205,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["nu17132211"],"URL":"https:\/\/doi.org\/10.3390\/nu17132211","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]}}}